OOIR: Observatory of International Research

Papers

(The median citation count of JACC: Cardiooncology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Full Issue PDF	126
Editorial Board	120
Full Issue PDF	109
Full Issue PDF	98
Priorities in Cardio-Oncology	96
Balancing Promise and Evidence	72
Hormonal Therapy and Cardiovascular Health	71
To Anticoagulate or Not to Anticoagulate to Prevent Arterial Thrombosis During Systemic Cancer Therapy	69
Full Issue PDF	68
Atrial Fibrillation in Patients With Cancer	68
Prospective Screening for Transthyretin Cardiac Amyloidosis in Spinal Stenosis Surgery Patients	62
Epigenomics of Cardio-Oncology	59
Cardiovascular Safety in Oncology Clinical Trials	58
LAG3 Blockade Expands T Cells Within Atherosclerotic Plaque	56
SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes	55
Cancer Therapy and Exercise Intolerance: The Heart Is But a Part	55
Deep Inspiration Breath Hold in Left-Sided Breast Radiotherapy	53
Cardiac Risk Stratification Before Lung Cancer Radiation	51
Rivaroxaban Efficacy and Safety in SELECT-D Community Cancer-Associated Venous Thromboembolism Patients	50
Moving the Pendulum for Earlier Detection of Systolic and Diastolic Dysfunction in Cancer Survivors	49
Full Issue PDF	46
Assessing Neurohormonal Antagonist Withdrawal in HER2+ Breast Cancer Patients With CTRCD	45
Novel Technologies Must Be Considered for Childhood Cancer Survivors at Risk for Cardiomyopathy	43
CARDIAC, MUSCULAR, AND NEUROLOGICAL TOXICITY SECONDARY TO PEMBROLIZUMAB IN A PATIENT WITH MELANOMA	40
Long-Term, Implantable Event Monitoring of Patients With Wild-Type Transthyretin Cardiac Amyloidosis	38

Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms	38
Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis	37
Frailty	37
Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma	35
Cardiac Substructure Radiation Dose and Associations With Tachyarrhythmia and Bradyarrhythmia After Lung Cancer Radiotherapy	34
PROPORTIONATE AND ABSOLUTE PULMONARY EMBOLISM MORTALITY IN ONCOLOGY IN THE UNITED STATES FROM 1999-2019	31
Atorvastatin Does Not Attenuate Aortic Stiffening After Doxorubicin for Breast Cancer and Lymphoma (PREVENT-WF-98213)	31
Editorial Board/Officers Page	31
Changes in Physical Activity and Cardiovascular Disease Risk in Cancer Survivors	30
Growth Differentiation Factor-15 Predicts Major Bleeding in Cancer Patients	30
Clonal Hematopoiesis in Cancer and Cardiovascular Disease	30
Peripheral Ischemia Fuels Breast Cancer Via Myeloid-Skewed Hematopoiesis	30
Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD	30
Correlation of Natriuretic Peptides with Invasively Measured Intracardiac Filling Pressures in Patients With Cancer	28
Risk Stratification for Trastuzumab-Induced Cardiac Dysfunction and Potential Implications for Surveillance	26
Permissive Cardiotoxicity	26
Full Issue PDF	24
Risk for Myocardial Infarction Following 5-Fluorouracil Treatment in Patients With Gastrointestinal Cancer	24
Editorial Board	24
Cancer Immunotherapy Beyond Checkpoint Blockade	24
SUCCESSFUL DIAGNOSIS AND SURGICAL RESECTION OF A PULMONIC SARCOMATOID CARCINOMA LACKING PET AVIDITY OR MALIGNANT APPEARING CMR TISSUE CHARACTERISTICS	23
TRASTUZUMAB CARDIOTOXICITY IN EARLY STAGE HER2 POSITIVE BREAST CANCER PATIENTS IN MEXICO	22
Leveling Up	22
Coronary Artery Calcium Scores After Prophylactic Premenopausal Bilateral Salpingo-Oophorectomy	22
The Association of Malignancy With Stroke and Bleeding in Atrial Fibrillation	22
Endothelin-1	22
Developing a Model for Cross-Institutional Educational Collaborations	22
Reply	21
Mismatch Between Preclinical Cardio-Oncology and Clinical Oncology Research	21
Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity	21
Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity	21
Quality-of-Care Measures for Cardio-Oncology	21
Artificial Intelligence to Complement, Not Replace, Clinical Knowledge	20
Dantrolene as a Potential Strategy to Prevent Doxorubicin-Induced Cardiotoxicity	20
A CHALLENGING CASE OF A LARGE RIGHT HEART MASS COMPLICATED BY COMPLETE HEART BLOCK	20
The United Kingdom’s First Cardio-Oncology Service	20
Genetic Testing in Evaluating Risk of Anthracycline Cardiomyopathy	20
Outcomes of Patients With Myeloproliferative Neoplasms Admitted With Myocardial Infarction	20
Deep Inspiration Breath Hold to Reduce Cardiovascular Disease Risk for Breast Radiotherapy	20
Vascular Complications of Atrial Fibrillation in Patients With Cancer	20
Low QRS Voltages in Cardiac Amyloidosis	19
CHA2DS2-VASc Score in Cardio-Oncology	18
Full Issue PDF	18
Cardiovascular Burden and Adverse Events in Patients With Esophageal Cancer Treated With Chemoradiation for Curative Intent	18
Fluoropyrimidine Therapy in Gastrointestinal Cancer	18
Prognosis After Withdrawal of Cardioprotective Therapy in Patients With Improved Cancer Therapeutics–Related Cardiac Dysfunction	18
Enalapril for Preventing Cardiotoxicity After High-Dose Anthracycline Therapy in Breast Cancer and Lymphoma Patients	18
Heart Failure Readmission in Patients With ST-Segment Elevation Myocardial Infarction and Active Cancer	17
High-Sensitivity Troponin I	17
Prognosis of MPN Patients Experiencing Acute Thrombotic Events and the Potential Role of Cytoreduction	17

Assessing Silent Cardiotoxicity in Long-Term Lymphoma Survivors Treated With Radiotherapy	17
Racial and Ethnic Disparities in All-Cause and Cardiovascular Mortality Among Cancer Patients in the U.S.	17
Imaging Immune Checkpoint Inhibitor Myocarditis	17
Endoplasmic Reticulum Selective Autophagy Alleviates Anthracycline-Induced Cardiotoxicity	17
Diet and Prevention of Cardiovascular Disease and Cancer	17
Baseline Cardiac Parameters as Biomarkers of Radiation Cardiotoxicity in Lung Cancer	16
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia	16
To Adjudicate or Not Adjudicate	16
Full Issue PDF	15
Harnessing iPSCs to Dissect Causality in Anthracycline-Induced Cardiotoxicity	15
How to Perform Hematopoietic Stem Cell Transplantation	15
Cardiovascular Risk Assessment in Patients With Kidney Cancer	15
Second Malignancies and Cardiovascular Disease in Childhood Cancer Survivors	14
Hearts on the Minds of Oncologists	14
ABSTRACT WITHDRAWN	14
Detection of Subclinical Cardiovascular Disease by Cardiovascular Magnetic Resonance in Lymphoma Survivors	14
SEX DIFFERENCES IN ANTHRACYCLINE-TREATED CANCER SURVIVORS ASSESSED BY CARDIOVASCULAR MAGNETIC RESONANCE IMAGING	14
FULL ISSUE PDF	14
Incident Myocardial Infarction, Heart Failure, and Oncologic Outcomes in Breast Cancer Survivors	13
Author Index	13
Cancer Therapy–Related Cardiac Dysfunction	12
A New Risk Factor for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy?	12
Cardiovascular Considerations After Cancer Therapy	12
Association of Midlife Cardiovascular Health and Subsequent Change in Cardiovascular Health With Incident Cancer	12
What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor–Induced Myocarditis?	12
Optimal Timing of a Physical Exercise Intervention to Improve Cardiorespiratory Fitness	11
(Less) Time and Energy	11
PREVALENCE OF IMPAIRED CARDIORESPIRATORY FITNESS & ITS CONTRIBUTORS IN LUNG CANCER PATIENTS PRIOR TO RADIOTHERAPY	11
A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid Cardiomyopathy	11
JACC: CardioOncology	11
PALLIATIVE RESECTION OF A CARDIAC SARCOMA	11
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors	11
PULMONARY VASCULAR TOXICITY WITH TYROSINE KINASE INHIBITOR THERAPY: A RARE CASE IN A CHRONIC MYELOID LEUKEMIA PATIENT	11
Guiding Treatment With Recovered CTRCD	11
Reply	10
Cardiovascular Care After Cancer	10
Addressing the Overlooked	10
Considerations of Competing Risks Analysis in Cardio-Oncology Studies	10
Racial Differences in Chronic Stress/Allostatic Load Variation Due to Androgen Deprivation Therapy in Prostate Cancer	10
Full Issue PDF	10
Navigating the Uncharted	10
Reply	10
The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity	10
Reply	10
Evaluating Anticoagulant Strategies for Atrial Fibrillation in Patients With Cancer	10
Clinical Practice Guidelines in Cardio-Oncology	10
Preventing Cancer Therapy–Related Cardiotoxicity	10
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction	10
The Cause of Death in Patients With Cancer	10
Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors	10
Reply	9
High-Sensitivity Cardiac Troponin I for Long-Term Cardiovascular Risk Stratification in a Cancer Clinic Population	9
ASYMPTOMATIC CARDIAC METASTASIS OF NEUROENDOCRINE TUMOR DIAGNOSED BY PET CT SCAN	9
Postural Orthostatic Tachycardia Syndrome and Orthostatic Hypotension Following Hematopoietic Stem Cell Transplantation	9
Genetic Susceptibility for Anthracycline-Induced Cardiomyopathy	9
When Clot Is Tumor	9
TYROSINE KINASE INHIBITOR ASSOCIATED POLYMORPHIC VENTRICULAR TACHYCARDIA	9
The ESC Cardio-Oncology Guidelines	9
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Preclinical Cardiotoxicity Screening in Cardio-Oncology	9
Reply	9
Editorial Board/Officers Page	9
ELECTROPHYSIOLOGIC PROPERTIES OF HEART BLOCK INDUCED BY IMMUNE CHECKPOINT INHIBITOR MYOCARDITIS FROM CEMIPLIMAB	9
Impact of Pre-Existing Frailty on Cardiotoxicity Among Breast Cancer Patients Receiving Adjuvant Therapy	8
Growing, Building, and Defining the Field of Cardio-Oncology for Our Patients	8
FIRST DOSE ORTHOSTATIC HYPOTENSION FOLLOWING DOCETAXEL AND GEMCITABINE INFUSION	8
ROCK and Rolling Towards Predicting BCR-ABL Kinase Inhibitor-Induced Vascular Toxicity	8
Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Cancer Patients	8
Learning From Trials	8
Assessing STEMI Outcomes in Patients With Cancer	8
Genomics for Improving Heart Failure Risk Assessment in Cancer Patients	8
Cancer Diagnosis, Physical Activity, and Heart Disease Risk	8
A Biomarker-Based Diagnostic Model for Cardiac Dysfunction in Childhood Cancer Survivors	8
Overcoming LGBTQI+ Disparities in Cardio-Oncology	8
Full Issue PDF	8
Editorial Board	8
LAG3 Regulates T Cell Activation and Plaque Infiltration in Atherosclerotic Mice	7
Longitudinal Patterns of Cardiovascular Disease and Cancer Mortality in Renal Cell Carcinoma Patients by Tumor Stage	7
Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma	7
Cardiac Biomarkers in Patients With Suspected Amyloid (Transthyretin) Cardiomyopathy	7
Reply	7

Reply	7
Reply	7
The Association of Metformin With Heart Failure in Patients With Diabetes Mellitus Receiving Anthracycline Chemotherapy	7
Physical Inactivity, Adverse Body Composition, and Cardiac Function in Breast Cancer Survivors	7
Pumping Up the Standards	7
Predicting Left Ventricular Dysfunction in Childhood Cancer Survivors	7
Cardiotoxicity of BRAF/MEK Inhibitors According to HFA/ICOS Cardiotoxicity Risk Category	7
Cardiovascular Concerns, Cancer Treatment, and Biological and Chronological Aging in Cancer	7
Melanoma Treatment	7
Blood Pressure Lowering and Risk of Cancer	7
Cardiovascular Disease With Hormone Therapy and Ovarian Suppression in Premenopausal Breast Cancer Survivors	6
Shared Mechanisms in Cancer and Cardiovascular Disease: S100A8/9 and the NLRP3 Inflammasome	6
Longitudinal Right Ventricular Systolic Function Changes in Breast Cancer Patients Treated With Cardiotoxic Cancer Therapy	6
MARANTIC ENDOCARDITIS - DIAGNOSTIC AND MANAGEMENT CHALLENGES	6
Modifiable Cardiometabolic Risk Factors in Survivors of Childhood Cancer	6
Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor–Induced Myocarditis	6
Adiposity and Muscle Strength in Men With Prostate Cancer and Cardiovascular Outcomes	6
Recognizing and Responding to Cardiac Risk With Osimertinib	6
Full Issue PDF	6
Editorial Board	6
Reduced Thoracic Aortic Distensibility Upon Breast Cancer Diagnosis (WF-97415 and WF-98213)	6
Risk of Incident Heart Failure Among Young Adult Cancer Survivors	6
New Cardiotoxicity Risk Assessment Guidelines	6
Leukemia and Heart Disease	6
Immune Checkpoint Inhibitor Myocarditis and Cellular Rejection in Orthotopic Heart Transplant Recipients	6
Incident Cancer in Heart Failure Patients and the Need for Additional Investigations	6
Rarefaction of Blood, But Not Lymphatic Capillaries, in Patients With Cardiac Amyloidosis	6
Mitigation of Doxorubicin Cardiotoxicity With Synergistic miRNA Combinations Identified Using Combinatorial Genetics en masse (CombiGEM)	6
Ablating Late Cardiovascular Events in Modern Hematopoietic Cell Transplantation	6
Reply	5
Diagnostic Performance of the New Free Light Chain Ratio in Systemic Amyloidosis	5
Editorial Board	5
Cancer-Associated Venous Thromboembolism	5
Exercise Training in Breast Cancer Survivors	5
Assessing the Certainty of Evidence on Efficacy and Safety of Anticoagulants for Cancer-Associated Thrombosis	5
AL Amyloidosis for Cardiologists	5
Effect of Tafamidis on Renal Function in Patients With Transthyretin Amyloid Cardiomyopathy in ATTR-ACT	5
Potential and Pitfalls of Pharmacovigilance Databases in Oncology	5
Predictors of Atrial Fibrillation After Thoracic Radiotherapy	5
Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies	5
Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors	5
Mediterranean Diet Is Associated With Lower All-Cause and Cardiovascular Mortality Among Long-Term Cancer Survivors	5
The Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Anthracycline-Treated Patients With Cancer	5
Reply	5
More Data to Support a Cardiac-Oncologic Partnership	5
Articulating the JACC Journals’ Direction in Times of Global Change	5
Determinants of Impaired Peak Oxygen Uptake in Breast Cancer Survivors: JACC: CardioOncology Primer	4
Haptoglobin Gene Expression and Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors	4
Significance of Alectinib-Induced Bradycardia	4
Full Issue PDF	4
Reply	4
Probing the Anthracycline-Induced Myocardial Injury	4
Troponin Surveillance in Patients Receiving Immune Checkpoint Inhibitors	4
Bridging the Knowledge Gap for Older Patients With CLL on Ibrutinib	4
Steroids in Immune Checkpoint Inhibitor Myocarditis	4
Editorial Board	4
Epidemiology and Antithrombotic Therapy for Cancer-Associated Arterial Thromboembolism in Japan	4
Editorial Board/Officers Page	4
Arterial Thromboembolism in Patients With AF and CHA2DS2-VASc Score 0-2 With and Without Cancer	4
SARCOIDOSIS MIMICKING CARDIAC AMYLOIDOSIS: A CHALLENGING CONUNDRUM	4
Personalized Trastuzumab-Induced Cardiac Dysfunction Risk Stratification and Surveillance	4
Cardiovascular Disease in Myeloproliferative Neoplasms	4
Editorial Board/ACC Officers Page	4
Is Preventative Oophorectomy Safe?	4
Cardiovascular Disease After Hematopoietic Stem Cell Transplantation in Adults	4
The FLC Ratio Reframed	3
Screening for Coronary Artery Disease in Cancer Survivors	3
How Common Is Pre-Existing Cardiovascular Disease in Cancer Patients	3
Outcomes and Predictors of Severity of Immunotherapy-Related Myocarditis	3
Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity	3
Health Literacy, Individual and Community Engagement, and Cardiovascular Risks and Disparities	3
Embracing the Power of the Polysocial Risk Score	3
Full Issue PDF	3
Targeting Cardiovascular Adverse Events of Metastatic Renal Cell Carcinoma Therapies	3
Editorial Board	3
Risk of Heart Failure Hospitalization in Patients Treated With Osimertinib	3
Cardio-Oncology Care Delivery for All Patients With Cancer Within Academic and Community Settings	3
SGLT2 Inhibitors in Mitigating Cancer Therapy-Related Cardiac Dysfunction	3
Cardio-Oncology and Health Equity	3
Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions	3
Risk of Hematologic Malignancies in Patients With Acute Myocardial Infarction	3
Increased Cardiac Risk After a Second Malignant Neoplasm Among Childhood Cancer Survivors	3
Reversible Myocardial Edema Secondary to Tagraxofusp-Induced Capillary Leak Syndrome	3
Effects of Aerobic Exercise on Cardiorespiratory Fitness and Cardiovascular Risk Factors in Long-Term Breast Cancer Survivors	3
Walk Your Way Out of Cardiovascular Risk	3
CARDIOVASCULAR DISEASE RISK CONTROL IN SURVIVORSHIP: THE ROLE AND IMPLEMENTATION OF CARDIO-ONCOLOGY SERVICES	3
Raise the Flag	3
Imaging-Based Obesity Assessment for Risk Factor Stratification and Prognostication in Malignancy	3
How to Treat Prostate Cancer With Androgen Deprivation and Minimize Cardiovascular Risk	3
ER-Specific Autophagy or ER-Phagy in Cardiac Myocytes Protects the Heart Against Doxorubicin-Induced Cardiotoxicity	3
How to Manage and Monitor Cardiac Dysfunction in Patients With Metastatic HER2-Positive Breast Cancer	3
Full Issue PDF	3
Longitudinal Strain and Troponin I Elevation in Patients Undergoing Immune Checkpoint Inhibitor Therapy	2
Rechallenge After Severe Immune Checkpoint Inhibitor Myocarditis	2
Clonal Hematopoiesis Is Associated With Cardiomyopathy During Solid Tumor Therapy	2